A Review of the Use of Secukinumab for Psoriatic Arthritis

Overview

Journal Rheumatol Ther

Specialty Rehabilitation Medicine

Date 2017 Aug 30

PMID 28849401

Citations 8

Authors

Nupur U Patel

Nora C Vera

Emily Rose Shealy

Margaret Wetzel

Steven R Feldman

Affiliations

Soon will be listed here.

Abstract

Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy associated with psoriasis (PsO). Treatment options range from non-pharmacologic measures to NSAIDS, DMARDs, and biologics, depending on patient presentation. Secukinumab (Cosentyx©) is a new biologic treatment option that was approved for use in treating adult patients with PsA in October 2016. Our paper explores the clinical trial evidence available for secukinumab to examine its safety and efficacy as a therapeutic agent for the treatment of PsA. While indirect comparisons of indicate that secukinumab is as effective as other treatment options, further studies directly comparing available treatments will be necessary to establish its place in treatment guidelines. As these and other trials are conducted, the evidence produced will further elucidate the clinical potential of secukinumab as a treatment option for patients with rheumatologic disease.

Citing Articles

Understanding the mechanisms of actions of hydrolytic enzymes in the immunopathogenesis of psoriasis and their inhibitors as treatment options.

Bharatha M, Nandana M, Vishwanath B, Rajaiah R Arch Dermatol Res. 2025; 317(1):357.

PMID: 39918641 DOI: 10.1007/s00403-025-03878-9.

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.

Alegre-Sancho J, Nunez-Monje V, Campos-Fernandez C, Balaguer-Trull I, Robustillo-Villarino M, Aguilar-Zamora M Front Med (Lausanne). 2023; 10:1294247.

PMID: 38053615 PMC: 10694458. DOI: 10.3389/fmed.2023.1294247.

Possible autoimmune hemolytic anemia induced by secukinumab: a case report.

Rahman P, Kalim H, Prawitasari S, Raharjo F Pan Afr Med J. 2022; 41:41.

PMID: 35317476 PMC: 8917466. DOI: 10.11604/pamj.2022.41.41.32191.

Global Risk of Bacterial Skin Infections and Herpesviridae Infections with Ustekinumab, Secukinumab, and Tumour Necrosis Factor-alpha Inhibitors: Spontaneous Reports of Adverse Drug Reactions from the World Health Organization Pharmacovigilance....

Davidson L, van den Reek J, van Hunsel F, de Jong E, Kullberg B Acta Derm Venereol. 2022; 102:adv00648.

PMID: 35088874 PMC: 9558332. DOI: 10.2340/actadv.v102.175.

Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview.

Schinocca C, Rizzo C, Fasano S, Grasso G, Barbera L, Ciccia F Front Immunol. 2021; 12:637829.

PMID: 33692806 PMC: 7937623. DOI: 10.3389/fimmu.2021.637829.

References

McInnes I, Mease P, Kirkham B, Kavanaugh A, Ritchlin C, Rahman P . Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386(9999):1137-46. DOI: 10.1016/S0140-6736(15)61134-5. View

Miossec P, Kolls J . Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012; 11(10):763-76. DOI: 10.1038/nrd3794. View

Lubberts E, Joosten L, Oppers B, van den Bersselaar L, Kolls J, Schwarzenberger P . IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol. 2001; 167(2):1004-13. DOI: 10.4049/jimmunol.167.2.1004. View

Coates L, Murphy R, Helliwell P . New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol. 2016; 174(6):1174-8. DOI: 10.1111/bjd.14667. View

Mease P, McInnes I . Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatol Ther. 2016; 3(1):5-29. PMC: 4999581. DOI: 10.1007/s40744-016-0031-5. View

Mease P, McInnes I, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D . Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015; 373(14):1329-39. DOI: 10.1056/NEJMoa1412679. View

Coates L, Kavanaugh A, Mease P, Soriano E, Acosta-Felquer M, Armstrong A . Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016; 68(5):1060-71. DOI: 10.1002/art.39573. View

Raychaudhuri S, Raychaudhuri S, Genovese M . IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2011; 359(1-2):419-29. DOI: 10.1007/s11010-011-1036-6. View

Miossec P, Korn T, Kuchroo V . Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009; 361(9):888-98. DOI: 10.1056/NEJMra0707449. View

10.

Oussedik E, Cardwell L, Patel N, Onikoyi O, Feldman S . An Anchoring-Based Intervention to Increase Patient Willingness to Use Injectable Medication in Psoriasis. JAMA Dermatol. 2017; 153(9):932-934. PMC: 5817439. DOI: 10.1001/jamadermatol.2017.1271. View

11.

Mease P, Gladman D, Helliwell P, Khraishi M, Fuiman J, Bananis E . Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2014; 71(4):649-55. DOI: 10.1016/j.jaad.2014.05.010. View

12.

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P . Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015; 373(26):2534-48. DOI: 10.1056/NEJMoa1505066. View

13.

Menon B, Gullick N, Walter G, Rajasekhar M, Garrood T, Evans H . Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014; 66(5):1272-81. PMC: 4158887. DOI: 10.1002/art.38376. View

14.

van de Kerkhof P, Griffiths C, Reich K, Leonardi C, Blauvelt A, Tsai T . Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016; 75(1):83-98.e4. DOI: 10.1016/j.jaad.2016.03.024. View

15.

Gottlieb A, Korman N, Gordon K, Feldman S, Lebwohl M, Koo J . Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008; 58(5):851-64. DOI: 10.1016/j.jaad.2008.02.040. View

16.

Gossec L, Coates L, de Wit M, Kavanaugh A, Ramiro S, Mease P . Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016; 12(12):743-750. DOI: 10.1038/nrrheum.2016.183. View

17.

McInnes I, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs J . Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2013; 73(2):349-56. DOI: 10.1136/annrheumdis-2012-202646. View

18.

Porter M, Lockwood S, Kimball A . Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017; 3(1):21-25. PMC: 5419021. DOI: 10.1016/j.ijwd.2016.12.003. View

19.

Kavanaugh A, Mease P, Gomez-Reino J, Adebajo A, Wollenhaupt J, Gladman D . Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014; 73(6):1020-6. PMC: 4033106. DOI: 10.1136/annrheumdis-2013-205056. View

20.

Koenders M, van den Berg W . Secukinumab for rheumatology: development and its potential place in therapy. Drug Des Devel Ther. 2016; 10:2069-80. PMC: 4928657. DOI: 10.2147/DDDT.S105263. View